As part of the assessment of immune correlates of protection, many randomized, placebo-controlled COVID-19 vaccine efficacy trials measure Spike protein sequences from symptomatic COVID-19 endpoint cases, and sometimes also from SARS-CoV-2 asymptomatic infections. The gene discussed is CHMP5; the disease is COVID-19.